Lamivudine NDC 60505-3251

NDC codes

FDA NDC Directory

Product NDC (as listed)60505-3251Labeler and product segments. Claims need a package NDC.

Product NDC at billing width60505-3251Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
60505-3251-6	60505325106	60 TABLET, FILM COATED in 1 BOTTLE (60505-3251-6)Marketed from Dec 2, 2011
60505-3251-8	60505325108	1000 TABLET, FILM COATED in 1 BOTTLE (60505-3251-8)Marketed from Dec 2, 2011

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Lamivudine
Generic name (nonproprietary): lamivudine
Active ingredients: Lamivudine — 150 mg/1
Dosage form: Tablet, Film coated
Route: Oral
Labeler: Apotex Corp.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 091606
Marketing start: Dec 2, 2011
Listing expires: Dec 31, 2026
Other FDA classes: Nucleoside Reverse Transcriptase Inhibitors (Mechanism)
Identifiers: Product ID 60505-3251_2cca5476-aba6-0525-0bb5-890f2ca25bb7SPL ID 2cca5476-aba6-0525-0bb5-890f2ca25bb7SPL set ID 34c02bcc-d6ff-99d4-8e6a-4a91908adca8RxCUI 199147, 349491UNII 2T8Q726O95
Pharmacologic class: Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor; Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N460505325106 followed by a unit qualifier and the quantity

Package 60505-3251-06. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Sep 19, 2025. This label includes a boxed warning.

Indications (excerpt from the label)

Lamivudine tablets are a nucleoside analogue indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. Limitations of Use: The dosage of this product is for HIV-1 and not for HBV. Lamivudine tablets are a nucleoside analogue reverse transcriptase inhibitor indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. Limitations of Use: The dosage of this product is for HIV-1 and not for HBV. ( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 091606

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 091606
Product	Strength	Form · route	Labeler	Product NDC
Lamivudine	Lamivudine 300 mg/1	Tablet, Film coatedOral	Apotex Corp.	60505-3252
Lamivudine	Lamivudine 300 mg/1	Tablet, Film coatedOral	Golden State Medical Supply, Inc.	60429-354
Lamivudine	Lamivudine 150 mg/1	Tablet, Film coatedOral	Golden State Medical Supply, Inc.	60429-353
Lamivudine	Lamivudine 150 mg/1	Tablet, Film coatedOral	Major Pharmaceuticals	0904-6583
Lamivudine	Lamivudine 150 mg/1	Tablet, Film coatedOral	American Health Packaging	60687-720